Retatrutide Starting Dose: Why Phase 2 Began at 2 mg

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• The phase 2 retatrutide trial used 2 mg subcutaneous once-weekly as the starting dose for participants targeting 4 mg, 8 mg, or 12 mg
• The 2 mg start was selected from phase 1 ascending-dose data; it was the highest dose with acceptable tolerability without prior titration
• Titration steps every 4 weeks allow plasma steady state and gastric adaptation to develop before the next increment
• The trial starting dose is published research, not a prescription recommendation. Retatrutide is investigational and not FDA-approved
• FormBlends does not sell or supply retatrutide. Discuss any treatment plan with a licensed clinician.

Direct answer

In the phase 2 obesity trial, retatrutide was started at 2 mg once weekly by subcutaneous injection. This was the initial dose for everyone in the 4 mg, 8 mg, and 12 mg target arms. After 4 weeks at 2 mg, doses stepped up in 2 mg or 4 mg increments at 4-week intervals until the target was reached. The 2 mg starting dose reflected what phase 1 data showed adults could tolerate at week one without titration. It is a research protocol, not a label.

Table of contents

1. What the 2 mg starting dose looks like in the trial
2. How phase 1 informed the choice of 2 mg
3. Why titration matters for GI tolerance
4. Pharmacology behind the 4-week step
5. The 4 mg initial-dose sub-arm and what it found
6. Comparison with other GLP-1 starting doses
7. What the trial protocol cannot tell you
8. Contrary view: should the start be lower?
9. Decision framework
10. FAQ
11. Sources

What the 2 mg starting dose looks like in the trial

In Jastreboff et al. (NEJM 2023), participants assigned to a 4 mg, 8 mg, or 12 mg target received 2 mg of retatrutide on day one. They self-administered or had a clinician administer a single subcutaneous injection weekly. The injection day was kept consistent for each individual through the 48 weeks of treatment.

At week 5, participants stepped up. For the 4 mg target, they moved to 4 mg and stayed there. For the 8 mg target with the 2 mg initial subgroup, they moved to 4 mg at week 5 and 8 mg at week 9. For the 12 mg target, the schedule was 2 mg, then 4 mg at week 5, then 8 mg at week 9, then 12 mg at week 13.

One arm sat outside this structure: the 1 mg group. Those participants started and stayed at 1 mg for the full 48 weeks. They were the lowest-dose efficacy comparator.

How phase 1 informed the choice of 2 mg

Phase 1 retatrutide work appeared in Diabetes Care and conference presentations from 2022. The relevant studies were a single-ascending-dose trial and a multiple-ascending-dose trial in healthy adults and adults with type 2 diabetes.

Three findings shaped the phase 2 starting choice:

• Doses up to 2 mg given without titration produced GI symptoms in a minority of participants, mostly mild
• Doses of 4 mg given without titration produced significant nausea or vomiting in a larger fraction, including some moderate-to-severe events
• Pharmacokinetic modeling indicated that 2 mg was sufficient to produce measurable GLP-1 receptor occupancy and early appetite effects

The selection logic was conservative. The trial design did not need 2 mg to be the maximum tolerated starting dose; it needed it to be a dose almost no one would drop out from in the first month.

Why titration matters for GI tolerance

Retatrutide hits three receptors at once. GLP-1 and GIP slow gastric emptying and increase satiety. Glucagon-receptor activity adds energy-expenditure effects. The dose-dependent side-effect profile is dominated by the slowed-stomach component, which is felt as nausea, fullness, occasional vomiting, and sometimes diarrhea or constipation.

Slow introduction lets the gut adapt. Gastric emptying rate, which retatrutide slows substantially in the first week of a new dose, partially normalizes over 2-4 weeks. Once that adaptation is in place, a higher dose can be added without the same intensity of acute symptoms.

This is not a retatrutide-specific phenomenon. Semaglutide and tirzepatide use the same logic. The reason retatrutide titration goes to higher absolute numbers is that the drug's potency requires the higher dose for full effect, not that the adaptation mechanism is different.

Pharmacology behind the 4-week step

Retatrutide has a long half-life, similar in scale to semaglutide and tirzepatide. Plasma steady state after a dose change takes roughly 5-6 weeks based on standard half-life arithmetic. Four weeks is shy of full steady state, which is intentional: it gets close enough that the next step lands on a stable enough plasma profile to interpret tolerability.

If the step were three weeks, plasma concentration at the existing dose would not have plateaued. A patient who felt fine on day 14 might feel worse on day 21 just from continued accumulation. Stepping up at that point would conflate adaptation with continued plasma rise.

If the step were eight weeks, the schedule would extend the total titration period to roughly 32 weeks for the 12 mg target. The phase 2 design aimed for participants to spend most of the study window at target dose, which set an upper bound on step length.

The 4 mg initial-dose sub-arm and what it found

The 8 mg target arm was split into two subgroups. One started at 2 mg, the other at 4 mg. Both reached 8 mg by week 9 but on slightly different timing.

The published readout showed:

• Comparable mean weight loss between the two initial-dose groups at 48 weeks
• More early adverse events in the 4 mg initial group
• Somewhat higher early discontinuation in the 4 mg initial group

This suggested that starting higher does not improve outcomes but does worsen tolerability. The 2 mg start remains the published reference. Phase 3 protocols have generally followed it.

Comparison with other GLP-1 starting doses

Drug	Starting dose	Step size	Step interval	Highest tested target
Retatrutide (phase 2)	2 mg	2-4 mg	4 weeks	12 mg
Tirzepatide (Zepbound)	2.5 mg	2.5 mg	4 weeks	15 mg
Semaglutide (Wegovy)	0.25 mg	0.25-0.5 mg	4 weeks	2.4 mg
Liraglutide (Saxenda)	0.6 mg	0.6 mg	1 week	3 mg

The absolute milligram numbers reflect drug-specific potency and receptor profile. They are not interchangeable. A patient comfortable at semaglutide 2.4 mg cannot translate that to a retatrutide dose by ratio; the drugs hit different receptors at different affinities.

What the trial protocol cannot tell you

The 2 mg starting dose was selected for a homogeneous trial population: adults with obesity (BMI 30+ or 27+ with comorbidities), without major medical contraindications, monitored on a structured schedule. Real-world populations differ.

The trial does not tell us how a 70-year-old with mild kidney impairment should start. It does not tell us what happens when a patient skips a dose for two weeks and then resumes. It does not address pregnancy or lactation, where retatrutide has not been studied. These are individual clinical questions, not protocol questions.

The published starting dose is also not a guarantee. Some participants in the 2 mg group had significant GI symptoms in the first two weeks and benefited from delayed escalation. The protocol's 2 mg is the average safe starting point, not the safe starting point for everyone.

Contrary view: should the start be lower?

Two arguments support a sub-2 mg starting dose in some patients.

The lean-patient case. Retatrutide phase 2 enrolled adults with obesity. A leaner or smaller-bodied individual taking retatrutide off-label would receive a higher milligram-per-kilogram exposure at 2 mg than the trial average. A 60-kg adult getting 2 mg receives effectively 33 micrograms per kilogram. A 110-kg trial participant getting 2 mg receives roughly 18 micrograms per kilogram. The same milligram is a different dose at different body weights.

The history-of-GI-sensitivity case. A patient with a prior history of GLP-1 intolerance at low doses of semaglutide or tirzepatide may be more sensitive to retatrutide. Starting at 1 mg and titrating to 2 mg over the first 4 weeks would be a reasonable conservative variant. This has not been studied, but the pharmacology is consistent.

Neither argument has trial data behind it. Both are reasonable clinical hypotheses that a licensed clinician might apply individually.

Decision framework

If you are a patient considering retatrutide: there is no FDA-approved pathway. The clinical-trial population continues to expand through TRIUMPH phase 3 enrollment. The most realistic near-term option for similar weight-loss outcomes is FDA-approved tirzepatide. Discuss with a licensed clinician.

If you are a clinician evaluating starting dose: the 2 mg published starting dose has the largest evidence base. A lower start (1 mg) or a longer first step (2 mg for 8 weeks) are reasonable individualized variants in patients with GI sensitivity or low body weight. Document the reasoning.

If you are comparing to a GLP-1 you already take: milligram-to-milligram conversion between GLP-1 medications is not valid. Retatrutide is a different molecule with a different receptor profile.

Discuss with a licensed clinician.

FAQ

What was the retatrutide starting dose in phase 2? 2 mg once weekly by subcutaneous injection for adults targeting 4 mg, 8 mg, or 12 mg. The 1 mg arm stayed at 1 mg the entire study.

Why does retatrutide need a low starting dose? Triple-receptor activity produces dose-dependent gastrointestinal effects. The 2 mg dose was selected from phase 1 data as the highest dose with broadly acceptable tolerability without prior titration.

Does the starting dose produce weight loss? Some. The 1 mg arm reached ~8.7% mean weight loss at 48 weeks. The 2 mg starting weeks during escalation are not a target dose; they are a ramp-up.

Why is titration spaced at 4 weeks? Four weeks allows plasma levels to approach steady state and gastric adaptation to develop before the next increment.

Can a different starting dose be used? Retatrutide is not FDA-approved, so there is no prescription dose. Off-protocol variants exist clinically. None have published efficacy data behind them.

What if 2 mg causes too much nausea? Delayed escalation is the standard adjustment. Some trial participants held at 2 mg for an extra 4 weeks before stepping up.

How does retatrutide start compare to tirzepatide? Tirzepatide starts at 2.5 mg with 2.5 mg steps. Retatrutide starts at 2 mg with 2-4 mg steps. Patterns are similar; absolute milligrams are not interchangeable.

Related guides

• The Retatrutide Dose Schedule Used in Phase 2 Trials
• Retatrutide Results by Starting BMI: Expected Timelines
• Is Retatrutide Worth Waiting for vs Starting Semaglutide Now
• Is Retatrutide Safe? An Honest Read of the Phase 2 Data
• What Does Retatrutide Do? A Direct Look at the Phase 2 Numbers
• Does Retatrutide Cause Hair Loss? A Look at the Phase 2 Data and the Mechanism
• Tool: dosage calculator

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (A Phase 2 Trial). New England Journal of Medicine. 2023.
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023.
3. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022.
4. Urva S et al. Pharmacokinetics and pharmacodynamics of retatrutide in healthy adults. Diabetes, Obesity and Metabolism. 2023.
5. ClinicalTrials.gov NCT05298254. Phase 2 dose-finding study of retatrutide for obesity.
6. ClinicalTrials.gov NCT05882045. TRIUMPH-1: phase 3 retatrutide in obesity.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
9. Pi-Sunyer X et al. Liraglutide for weight management (SCALE). NEJM. 2015.
10. FDA Drug Approvals Database (no retatrutide approval as of May 2026).
11. Endocrine Society Clinical Practice Guideline on Pharmacotherapy of Obesity. 2024 update.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients to independent licensed providers and U.S.-based pharmacies. Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, prescribe, or dispense retatrutide. This article is for educational purposes only.

Compounded Medication Notice. For medications other than retatrutide, FormBlends works with state-licensed 503A compounding pharmacies. Compounded preparations are not FDA-approved drugs and have not been reviewed by the FDA for safety, efficacy, or quality. They are prepared in response to individual prescriptions issued by licensed clinicians.

Results Disclaimer. Weight-loss figures cited reflect mean changes in the published phase 2 trial population over 48 weeks. Individual results vary substantially based on baseline weight, adherence, diet, exercise, and biological factors. Trial means are not personal predictions.

Trademark Notice. Retatrutide is an investigational compound from Eli Lilly and Company. Mounjaro and Zepbound are registered trademarks of Eli Lilly. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any company referenced above.